Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors | Zendy

Aramesh Saremi | Zendy; Dawn C. Schwenke | Zendy; Thomas A. Buchanan | Zendy; Howard N. Hodis | Zendy; Wendy J. Mack | Zendy; MaryAnn Banerji | Zendy; George A. Bray | Zendy; Stephen Clement | Zendy; Robert R. Henry | Zendy; Abbas E. Kitabchi | Zendy; Sunder Mudaliar | Zendy; Robert E. Ratner | Zendy; Frankie B. Stentz | Zendy; Nicolas Musi | Zendy; Devjit Tripathy | Zendy; Ralph A. DeFronzo | Zendy; Peter D. Reaven | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors

Author(s) -

Aramesh Saremi,

Dawn C. Schwenke,

Thomas A. Buchanan,

Howard N. Hodis,

Wendy J. Mack,

MaryAnn Banerji,

George A. Bray,

Stephen Clement,

Robert R. Henry,

Abbas E. Kitabchi,

Sunder Mudaliar,

Robert E. Ratner,

Frankie B. Stentz,

Nicolas Musi,

Devjit Tripathy,

Ralph A. DeFronzo,

Peter D. Reaven

Publication year - 2012

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.112.300346

Subject(s) - pioglitazone , prediabetes , medicine , diabetes mellitus , dyslipidemia , insulin resistance , endocrinology , placebo , adiponectin , type 2 diabetes , alternative medicine , pathology

To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research